

# Program of the 7<sup>th</sup> Tsurui Lymphoma Workshop

Feb. 24, 2023 (Fri)

Presentation and discussion, in English

9:00 Opening Remarks Junji Suzumiya

9:00 – 12:00

Section 1. T/NK-cell lymphomas, including ATL

Moderators: Ritsuro Suzuki, Motoko Yamaguchi

- 1) Won Seog Kim (30 min) What is the next step after chemotherapy in ENKTL?
- 2) Mamiko Sakata-Yanagimoto (30 min) How to create a new scientific world in lymphomas? My experience and future perspectives.
- 3) Atae Utsunomiya (30 min) Progress in the treatment of adult T-cell leukemia/lymphoma.
- 4) Francine M. Foss (30 min) Rare Subtypes of Peripheral T cell Lymphomas.
- 5) Shigeo Mori (30 min) Molecular bases of lymphoma classification: current status and tomorrow.

Discussion (30 min)

12:00 – 1:00

Luncheon Seminar. Chaired by Junji Suzumiya

Francine M. Foss. Progress and future of treatments for T cell lymphomas . . . based on the molecular pathogenesis

1:00 – 3:00

Section 2. Novel treatment strategies for lymphoma

Moderators: Akihiro Shimosaka, Koji Izutsu

- 1) Hideki Goto (30 min) Key points for successful use of CAR T-cell therapy
- 2) Linda Hanssens (30 min) Development of novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- 3) Miki Ando (30 min) iPSC-derived dual-antigen receptor T cell therapy for EBV-associated lymphomas
- 4) Akihiro Shimosaka (10 min) Commentary

Discussion (20 min)

3:00 – 3:30 Coffee break

3:30 – 6:00

### Section 3. Multiple myeloma

Moderators: Kosei Matsue, Akira Sakai

- 1) Teru Hideshima (40 min) New era of immunomodulatory drugs: target protein degradation therapy in multiple myeloma
- 2) Naoki Hosen (40 min) New targets for CAR-T cell therapy against multiple myeloma
- 3) Paul G. Richardson (40 min) The treatment of multiple myeloma in the past, present, and future – towards functional cure?

Discussion 30 min

6:00 Closing Remarks Kazuo Oshimi

### Guest speakers of the 7th Tsurui Lymphoma Workshop

Won Seog Kim; Professor, Samsung Medical Center, Sungkyunkwan University School of Medicine.

Mamiko Sakata-Yanagimoto; Professor, Department of Hematology, University of Tsukuba.

Atae Utsunomiya; Honorary Director, Department of Hematology, Imamura General Hospital, Kagoshima.

Francine M. Foss; Professor, Yale Cancer Center, Yale University School of Medicine.

Shigeo Mori; Professor Emeritus, Department of Pathology, Institute of Medical Science, University of Tokyo.

Hideki Goto; Instructor, Department of Hematology, Hokkaido University School of Medicine.

Linda Hanssens; Head of Medical Affairs, Miltenyi Biomedicine.

Miki Ando; Professor, Department of Hematology, Juntendo University School of Medicine.

Teru Hideshima; Principal Associate in Medicine, Dana-Farber Cancer Institute, Harvard Medical School.

Naoki Hosen; Professor, Department of Hematology and Oncology, Osaka University Graduate School of Medicine.

Paul G. Richardson; Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, RJ Corman Professor of Medicine, Harvard Medical School.

## **Moderators**

**Ritsuro Suzuki; Professor, Department of Hematology, Shimane University, School of Medicine.**

**Motoko Yamaguchi; Professor, Department of Hematological Malignancies, Mie University Graduate School of Medicine.**

**Akihiro Shimosaka; Chairperson, Asian Cellular Therapy Organization, Tokyo.**

**Koji Izutsu; Chief, Department of Hematology, National Cancer Center Hospital.**

**Kosei Matsue; Chief, Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa City, Chiba.**

**Akira Sakai; Professor, Department of Radiation Life Sciences, Fukushima Medical University.**

## **Backup Moderators**

**Section 1 Dr. Yasushi Isobe**

**Section 2 Dr. Jun Ando**

**Section 3 Dr. Kazuo Oshimi**